1.
|
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DTC-96-001, NCI-V97-1337
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SKY0101-010, NCT00029523
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GMALL06, NCT00199108
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-94129, NCI-V95-0661
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 3 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DTC-92-001, NCI-V97-1338
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 6 mo. to under 21 at relapse
Sponsor: NCI
Protocol IDs: POG-9412, NCT00002704
|
|
7.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000510918, U01CA070019, AMC-048, NCT00392834
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-004414-17, DEPOCYLAN, NCT00388531
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Temporarily closed
Age: Less than 18
Sponsor: Other
Protocol IDs: CILI, 2011-002622-48, NCT01593488
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000065754, SKYEPHARMA-96-002, DTC-96-002, NCI-V97-1336, NCT00003073
|
Mobile | Español
